Junta de Andalucía
Consejería de Salud y Consumo
Fundación Progreso y Salud

FPS groups are looking for R3-R4 researchers who can apply for competitive HR grant from the 2024 call "*Acción C - **Programa Nicolás Monardes"*** of the *Servicio Andaluz de Salud (SAS)*. Specifically:

MODALITY C.2. PROMOTION OF CLINICAL-TRANSLATIONAL RESEARCH ACTIVITIES IN *SAS* CLINICAL UNITS THROUGH COLLABORATIVE PROGRAMMES WITH A RESEARCH GROUP FROM MIXED THEMATIC RESEARCH CENTRES IN WHICH *SAS* PARTICIPATES

Application submission: **expected to be launched in May.**

Total annual cost of contracts, according to scientific level (including gross salary, incentives and employer Social Security contribution in charge of the contracting entity):

NOTE: The scientific levels are assigned according to the score obtained by the candidates in the evaluation of their curriculum, based on the following distribution (Modality C.2 (over 45p)).

- Level A (more than 32,90p): 62.991,00 €
- Level B (between 29,25 y 32,90p): 61.197,00 €
- Level C (less than 29,25p): 55.475,00 €

Eligibility requirements (in case that they remain the same as in the last call (2023)) - Candidates should:

a) Have a **PhD degree,** with a **postdoctoral research career** in the field of biomedicine and health sciences of **more than eight years**.

b) Be a **research group leader** of a health or research centre in the field of biomedicine and health sciences. The term "research group leader" refers to the person who coordinates a group of researchers organised around one or more common lines of scientific activity.

c) Have - at the time of submission of applications – at least one **line of research** related to the research group to which they are applying for. This line of research will also be related to one of the lines of the Clinical Unit of the *SAS* with which the collaborative translational research programme will be subscribed for the next four years.

d) Have an **outstanding level** of **scientific activity**. Specifically, the following minimum levels of scientific activity in the last 5 years (2019-2024) must be met:

1. Resources:

a1) Total projects: ≥ 1 active project/year, for at least four of the last five years.
a2) National and international project funding (PI): ≥ 70.000 euros.
a3) Projects as PI: ≥ 2.

Candidates must meet subcriteria a1, a2 and a3 to pass criterion 1.

Any of the following will be considered as merits equivalent to all of the above:

a4) International competitive financing as PI/CoPI/work package leader or equivalent, more than 70.000 euros for at least 3 years of the period.
a5) Total financing volume as PI/CoPI ≥ 300.000 euros, active for at least 3 years of the period.

Junta de Andalucía
Consejería de Salud y Consumo
Fundación Progreso y Salud

2. Knowledge generation:

b1) Publications in 1st decile ≥ 2, one of them, at least, led (first or last author or corresponding author).

b2) Publications in 1st quartile (including first decile) ≥ 4, three of them, at least, led (first or last author or corresponding author).

Candidates must meet subcriteria b1 and b2.

Important: In case that the candidate has the **I3/R3 certificate** of recognition as an **established researcher**, issued by the competent authority of the Government Administration, it will not be necessary to accredit compliance with the minimum levels of scientific activity defined in point d).

More information

Information on host group:

1. **Group:** Proteases and Extracellular Matrix**.**

Principal Investigator of the Group: Juan Carlos Rodríguez-Manzaneque. Pfizer - University of Granada - Junta de Andalucía Centre for Genomics and Oncological Research (GENYO).

Research line in which the candidate will work: Understanding tumor extracellular matrix to optimize the use of immunotherapies.

Summary of research line: The dynamic nature of tumor extracellular matrix contributes to the complex heterogeneity of tumors and its unpredicted response toimmunotherapies. Recent studies are remarking the importance of extracellular proteases as modulators of immune infiltration, withkey roles for tumor progression and opening new therapeutic strategies.

Profile of the desired candidate:

- Expertise in the study and characterization of cell populations in human tumors, using techniques such as immunohistochemistry, cytometry, multiplex, and others.
- Advanced knowledge and understanding of the complexity of tumor heterogeneity and use of immune therapies.
- In addition, knowledge of bioinformatic tools to analyze RNAseq and cancer-related big data will be positively considered.

More information about the research group here: Proteases and Extracellular Matrix

Principal Investigator contact: juancarlos.rodriguez@genyo.es

Junta de Andalucía
Consejería de Salud y Consumo
Fundación Progreso y Salud

2. Group: Metabolism, Immunology and Cardiovascular Risk**.**

Principal Investigator of the Group: Inés Pineda Torra. CABIMER (Andalusian Centre of Molecular Biology and Regenerative Medicine).

Research line in which the candidate will work: Impact of metabolic and environmental stressors and CV risk: sex differences.

Summary of research line: Overall, our studies focus on pathways predominant in cardiovascular disease (CVD), the leading cause of mortality for women worldwide. We are focusing our studies on women since they remain understudied and are significantly underrepresented in trials for cardiometabolic drugs. Cardiovascular risk factors, such as lipid profiles, change substantially in women during their lifetime. The main pathology underlying ischemic CVD is atherosclerosis, a process resulting from dysregulation and build-up of lipids with inflammation in the vascular wall. Innate and adaptive immune cells, such as monocytes and CD4+/Tregs and CD8+ Tcells, are key in the initiation and development of atherosclerosis. Women also show different immunological responses than men. Continuing from our studies exploring lipid metabolism in human immune cells and our work on cardiovascular risk in women with autoimmunity, we will now investigate cardiovascular risk in women from the general population at different life stages and uncover the underlying mechanisms to understand these changes.

Profile of the desired candidate:

- Research Field: biomedicine or computational analysis
- Research specialty: cardiovascular disease, metabolism, immunology, atherosclerosis, sex differences, transcriptomics, metabolomics, network analysis, multi-omic data integration analysis, machine learning (1-3 of the above would be desirable)

More information about the research group here: Metabolism, Immunology and Cardiovascular Risk

Principal Investigator contact: ines.pineda@cabimer.es

3. Group: Pancreatic Islet Development & Regeneration**.**

Principal Investigator of the Group: Benoit R. Gauthier. CABIMER (Andalusian Centre of Molecular Biology and Regenerative Medicine).

Research line in which the candidate will work: Development of novel delivery systems for anti-autoimmune disease pharmacological agents.

Junta de Andalucía
Consejería de Salud y Consumo
Fundación Progreso y Salud

Summary of research line: The candidate will pioneer the development and testing of cutting-edge drug delivery systems for autoimmune diseases in collaboration with the Functional Nanomaterial Chemistry Group (led by Dr. Noureddine Khiar el Wahabi) and the University Hospital Virgen Macarena (headed by Dr. María Asunción Martínez Brocca).

Profile of the desired candidate:

- PhD in Biochemistry with strong chemistry knowledge
- Drug development experience
- HIGH MOTIVATION

More information about the research group here: Pancreatic Islet Development & Regeneration

Principal Investigator contact: benoit.gauthier@cabimer.es

4. **Group:** Genetics of Complex Diseases.

Principal Investigator of the Group: Marta E. Alarcón Riquelme. Pfizer - University of Granada - Junta de Andalucía Centre for Genomics and Oncological Research (GENYO).

Research line in which the candidate will work: B Cells in autoimmunity.

Summary of research line: B cells are considered a major immune cell type in the development of autoimmunity. More recently, in the mouse, the age associated B cells have been studied as important in the development of lupus nephritis in the mouse models of the disease and in the human disease, also known as double negative 2 B cells (DN2).

Profile of the desired candidate:

- PhD in Immunology or Biochemistry with at least 8 years of postdoctoral experience, including international stays.
- Strong background in basic or clinical Immunology.
- Added value will be considered in the study of B cells in human conditions or mouse models. Both would be even better.
- Experience in preclinical models of autoimmune disease, particularly in mice.
- Experience in training masters and/or PhD students.

More information about the research group here: Genetics of Complex Diseases

Principal Investigator contact: marta.alarcon@genyo.es